Figure 4
Downregulation of PD-L1 expression after rapamycin treatment. (a) HepG2 cells were transfected with pCMV-PD-L1. After 48 h, the cells were incubated with rapamycin for an additional 24 h. The full-length blots are in Supplementary Fig. S9. (b) Densitometry intensity ratios for (a) from replicated western blots (WBs) (n = 3). **; p < 0.01. (c) HepG2 cells were transfected with pCMV-PD-L1. After 24 h, the cells were incubated for an additional 24 h with/without rapamycin and/or sorafenib at indicated concentrations. PD-L1, HK2, and β-actin levels were evaluated through WB. The full-length blots are in Supplementary Fig. S10. (d) Densitometry intensity ratios for (c) from replicated WB analyses (n = 3) *; p < 0.05, **; p < 0.01. (e) SK-Hep1 and SK-Hep1R cells were treated with IFN-γ (15 ng/mL). After 48 h, the cells were incubated for an additional 6 h with/without rapamycin at indicated concentrations. PD-L1, HK2, and β-actin levels were evaluated using WB. The full-length blots are shown in Supplementary Fig S11. (f) Densitometry intensity ratios for (e) from replicated WB (n = 3) **; p < 0.01.
